Travel Vaccines Market Size & Analysis Report – Global Opportunities & Forecast, 2019-2026
Travel Vaccines Market Size & Analysis Report, By Type (Monovalent Vaccines, Combination Vaccines), By Technology (Conjugate Vaccines, Live Attenuated Vaccines, Inactivated & Subunit Vaccines, Recombinant Vaccines, DNA Vaccines, Toxoid Vaccines), By Disease (Hepatitis A, Hepatitis B, Rabies, Typhoid, Japanese Encephalitis, Yellow Fever, Meningococcal, DPT, Varicella, Influenza, Others)
1. Executive Summary
2. Introduction
2.1. Study Objectives
2.2. Market Definition
2.2.1. Market Covered
2.2.2. Geographical Coverage
2.2.3. Study Years & Currency
2.3. Market Stakeholders
2.4. Key Questions this Study will Answer
2.5. GMI Research’s Approach & Methodology
3. Global Travel Vaccines Market - Overview
3.1. Introduction
3.2. Market Segmentation
3.3. Value Chain Analysis
3.4. Drivers
3.5. Restraints
3.6. Trends
4. Global Travel Vaccines Market Revenue Forecast till 2026
5. Global Travel Vaccines Market by Type Revenue Forecast till 2026
5.1. Monovalent Vaccines
5.2. Combination Vaccines
6. Global Travel Vaccines Market by Technology Revenue Forecast till 2026
6.1. Conjugate Vaccines
6.2. Live Attenuated Vaccines
6.3. Inactivated & Subunit Vaccines
6.4. Recombinant Vaccines
6.5. DNA Vaccines
6.6. Toxoid Vaccines
7. Global Travel Vaccines Market by Disease Revenue Forecast till 2026
7.1. Hepatitis A
7.2. Hepatitis B
7.3. Rabies
7.4. Typhoid
7.5. Japanese Encephalitis
7.6. Yellow Fever
7.7. Meningococcal
7.8. DPT
7.9. Varicella
7.10. Influenza
7.11. Others
8. Global Travel Vaccines Market by Geography Revenue Forecast till 2026
8.1. North America Travel Vaccines Market Revenue Forecast till 2026
8.1.1. North America Travel Vaccines Market by Type (Option 1: 25% customization)
8.1.1.1. Monovalent Vaccines
8.1.1.2. Combination Vaccines
8.1.2. North America Travel Vaccines Market by Technology
8.1.2.1. Conjugate Vaccines
8.1.2.2. Live Attenuated Vaccines
8.1.2.3. Inactivated & Subunit Vaccines
8.1.2.4. Recombinant Vaccines
8.1.2.5. DNA Vaccines
8.1.2.6. Toxoid Vaccines
8.1.3. North America Travel Vaccines Market by Disease
8.1.3.1. Hepatitis A
8.1.3.2. Hepatitis B
8.1.3.3. Rabies
8.1.3.4. Typhoid
8.1.3.5. Japanese Encephalitis
8.1.3.6. Yellow Fever
8.1.3.7. Meningococcal
8.1.3.8. DPT
8.1.3.9. Varicella
8.1.3.10. Influenza
8.1.3.11. Others
8.2. Europe Travel Vaccines Market Revenue Forecast till 2026
8.2.1. Europe Travel Vaccines Market by Type (Option 2: 25% customization)
8.2.1.1. Monovalent Vaccines
8.2.1.2. Combination Vaccines
8.2.2. Europe Travel Vaccines Market by Technology
8.2.2.1. Conjugate Vaccines
8.2.2.2. Live Attenuated Vaccines
8.2.2.3. Inactivated & Subunit Vaccines
8.2.2.4. Recombinant Vaccines
8.2.2.5. DNA Vaccines
8.2.2.6. Toxoid Vaccines
8.2.3. Europe Travel Vaccines Market by Disease
8.2.3.1. Hepatitis A
8.2.3.2. Hepatitis B
8.2.3.3. Rabies
8.2.3.4. Typhoid
8.2.3.5. Japanese Encephalitis
8.2.3.6. Yellow Fever
8.2.3.7. Meningococcal
8.2.3.8. DPT
8.2.3.9. Varicella
8.2.3.10. Influenza
8.2.3.11. Others
8.3. Asia-Pacific Travel Vaccines Market Revenue Forecast till 2026
8.3.1. Asia-Pacific Travel Vaccines Market by Type (Option 3: 25% customization)
8.3.1.1. Monovalent Vaccines
8.3.1.2. Combination Vaccines
8.3.2. Asia-Pacific Travel Vaccines Market by Technology
8.3.2.1. Conjugate Vaccines
8.3.2.2. Live Attenuated Vaccines
8.3.2.3. Inactivated & Subunit Vaccines
8.3.2.4. Recombinant Vaccines
8.3.2.5. DNA Vaccines
8.3.2.6. Toxoid Vaccines
8.3.3. Asia-Pacific Travel Vaccines Market by Disease
8.3.3.1. Hepatitis A
8.3.3.2. Hepatitis B
8.3.3.3. Rabies
8.3.3.4. Typhoid
8.3.3.5. Japanese Encephalitis
8.3.3.6. Yellow Fever
8.3.3.7. Meningococcal
8.3.3.8. DPT
8.3.3.9. Varicella
8.3.3.10. Influenza
8.3.3.11. Others
8.4. Rest of the World Travel Vaccines Market Revenue Forecast till 2026
8.4.1. Rest of the World Travel Vaccines Market by Type (Option 4: 25% customization)
8.4.1.1. Monovalent Vaccines
8.4.1.2. Combination Vaccines
8.4.2. Rest of the World Travel Vaccines Market by Technology
8.4.2.1. Conjugate Vaccines
8.4.2.2. Live Attenuated Vaccines
8.4.2.3. Inactivated & Subunit Vaccines
8.4.2.4. Recombinant Vaccines
8.4.2.5. DNA Vaccines
8.4.2.6. Toxoid Vaccines
8.4.3. Rest of the World Travel Vaccines Market by Disease
8.4.3.1. Hepatitis A
8.4.3.2. Hepatitis B
8.4.3.3. Rabies
8.4.3.4. Typhoid
8.4.3.5. Japanese Encephalitis
8.4.3.6. Yellow Fever
8.4.3.7. Meningococcal
8.4.3.8. DPT
8.4.3.9. Varicella
8.4.3.10. Influenza
8.4.3.11. Others
9. Competitive Landscape Analysis
10. Company Profiles (Option 5: 25% Customization - Profiles of 5 Additional Companies of your Choice)
10.1. Pfizer
10.1.1. Company Overview
10.1.2. Financials
10.1.3. Recent Developments
10.2. GlaxoSmithKline plc
10.2.1. Company Overview
10.2.2. Financials
10.2.3. Recent Developments
10.3. Merck & Co. Inc.
10.3.1. Company Overview
10.3.2. Financials
10.3.3. Recent Developments
10.4. Sanofi Pasteur
10.4.1. Company Overview
10.4.2. Financials
10.4.3. Recent Developments
10.5. Novartis
10.5.1. Company Overview
10.5.2. Financials
10.5.3. Recent Developments
10.6. ALK-Abello
10.6.1. Company Overview
10.6.2. Financials
10.6.3. Recent Developments
10.7. CSL Limited
10.7.1. Company Overview
10.7.2. Financials
10.7.3. Recent Developments
10.8. Medimmune LLC
10.8.1. Company Overview
10.8.2. Financials
10.8.3. Recent Developments
10.9. Bavarian Nordic
10.9.1. Company Overview
10.9.2. Financials
10.9.3. Recent Developments
10.10. Altimmune
10.10.1. Company Overview
10.10.2. Financials
10.10.3. Recent Developments
10.11. Abbott Laboratories
10.11.1. Company Overview
10.11.2. Financials
10.11.3. Recent Developments
10.12. F. Hoffman-La Roche Ltd.
10.12.1. Company Overview
10.12.2. Financials
10.12.3. Recent Developments
10.13. Crucell N.V
10.13.1. Company Overview
10.13.2. Financials
10.13.3. Recent Developments
11. About GMI Research
- Published Date: Feb-2019
- Report Format: Excel/PPT
- Report Code: UP208A-00-1219
Licensing Options
Single-User License:
The report is used by the purchaser (One Individual) only
Multi-User License:Report is shared with maximum 5 users (employees) including the purchaser of the purchasing corporation only
Corporate License:
Report is shared with unlimited user (employees) of the purchasing corporation only
The report is used by the purchaser (One Individual) only
Multi-User License:Report is shared with maximum 5 users (employees) including the purchaser of the purchasing corporation only
Corporate License:
Report is shared with unlimited user (employees) of the purchasing corporation only
Travel Vaccines Market Size & Analysis Report – Global Opportunities & Forecast, 2019-2026
$ 4,499.00 – $ 6,649.00
Why GMI Research
